Clinical trial
Seroquel in Bipolar Depression Versus Lithium
NCT00206141 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00206141 |
|---|---|
| Title | Seroquel in Bipolar Depression Versus Lithium |
| Official title | Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase 3 Study of the Efficacy & Safety of Quetiapine Fumarate & Lithium as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks & Quetiapine in Continuation (Abbreviated) |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bipolar Disorder, Bipolar Depression, Depression |
| Intervention type | Drug |
| Interventions | Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood) |
| Enrollment | 672 |
| Start date | Aug 1, 2005 |
| Completion | May 1, 2007 |
| First posted | Sep 21, 2005 |
| Last update posted | Jan 4, 2013 |
| Countries | Canada, Croatia, Estonia, Germany, Indonesia, Latvia, Lithuania, Malaysia, Norway, Philippines, Poland, Russia and 4 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: